FAR1
Fatty acyl-CoA reductase 1
Also known as: FACR1_HUMAN, FLJ22728, MLSTD2, SDR10E1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8WVX9
- Gene
- FAR1
- Ensembl
- ENSG00000197601
- Chromosome
- 11
- Canonical length
- 515 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Peroxisomes
OverviewNCBI Gene
The protein encoded by this gene is required for the reduction of fatty acids to fatty alcohols, a process that is required for the synthesis of monoesters and ether lipids. NADPH is required as a cofactor in this reaction, and 16-18 carbon saturated and unsaturated fatty acids are the preferred substrate. This is a peroxisomal membrane protein, and studies suggest that the N-terminus contains a large catalytic domain located on the outside of the peroxisome, while the C-terminus is exposed to the matrix of the peroxisome. Studies indicate that the regulation of this protein is dependent on plasmalogen levels. Mutations in this gene have been associated with individuals affected by severe intellectual disability, early-onset epilepsy, microcephaly, congenital cataracts, growth retardation, and spasticity (PMID: 25439727). A pseudogene of this gene is located on chromosome 13. [provided by RefSeq, Jan 2015]
Canonical amino-acid sequenceUniProt
515 residues, UniProt reviewed canonical sequence.
>Q8WVX9|FAR1
1 MVSIPEYYEG KNVLLTGATG FLGKVLLEKL LRSCPKVNSV YVLVRQKAGQ TPQERVEEVL
61 SGKLFDRLRD ENPDFREKII AINSELTQPK LALSEEDKEV IIDSTNIIFH CAATVRFNEN
121 LRDAVQLNVI ATRQLILLAQ QMKNLEVFMH VSTAYAYCNR KHIDEVVYPP PVDPKKLIDS
181 LEWMDDGLVN DITPKLIGDR PNTYIYTKAL AEYVVQQEGA KLNVAIVRPS IVGASWKEPF
241 PGWIDNFNGP SGLFIAAGKG ILRTIRASNN ALADLVPVDV VVNMSLAAAW YSGVNRPRNI
301 MVYNCTTGST NPFHWGEVEY HVISTFKRNP LEQAFRRPNV NLTSNHLLYH YWIAVSHKAP
361 AFLYDIYLRM TGRSPRMMKT ITRLHKAMVF LEYFTSNSWV WNTENVNMLM NQLNPEDKKT
421 FNIDVRQLHW AEYIENYCLG TKKYVLNEEM SGLPAARKHL NKLRNIRYGF NTILVILIWR
481 IFIARSQMAR NIWYFVVSLC YKFLSYFRAS STMRYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FAR1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Other membrane
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 62 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 62 nTPM
- spinal cord: 58 nTPM
- stomach: 54 nTPM
- esophagus: 47 nTPM
- duodenum: 34 nTPM
- rectum: 32 nTPM
Single-cell type
- neutrophils: 683 nCPM
- neutrophil progenitors: 670 nCPM
- foveolar cells: 433 nCPM
- oligodendrocytes: 391 nCPM
- mucous neck cells: 349 nCPM
- late spermatids: 341 nCPM
Immune cell
- neutrophil: 38 nTPM
- myeloid DC: 27 nTPM
- eosinophil: 26 nTPM
- classical monocyte: 24 nTPM
- intermediate monocyte: 20 nTPM
- non-classical monocyte: 18 nTPM
Brain region
- white matter: 174 nTPM
- medulla oblongata: 104 nTPM
- pons: 83 nTPM
- spinal cord: 81 nTPM
- cerebellum: 77 nTPM
- basal ganglia: 77 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FAR1.
Disease | AllUniProt
Conditions FAR1 is implicated in, by any mechanism.
- Peroxisomal fatty acyl-CoA reductase 1 disorder (PFCRD) MIM:616154
- Cataracts, spastic paraparesis, and speech delay (CSPSD) MIM:619338
Disease | GeneticClinVar
16 pathogenic / likely-pathogenic of 430 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Fatty acyl-CoA reductase 1 deficiency
- Spastic paraparesis-cataracts-speech delay syndrome
- CATARACTS, SPASTIC PARAPLEGIA, AND SPEECH DELAY
- FAR1-related neurodevelopmental disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.3
- gnomAD pLI
- 0.99
- gnomAD missense Z
- 3.3
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- ether lipid biosynthetic process
- glycerophospholipid biosynthetic process
- long-chain fatty-acyl-CoA metabolic process
- wax biosynthetic process
Molecular functions
- alcohol-forming long-chain fatty acyl-CoA reductase activity
- alcohol-forming very long-chain fatty acyl-CoA reductase activity
- oxidoreductase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of FAR1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FAR1 as an antibody target. Whether an autoantibody or antibody against FAR1 could matter depends on whether native FAR1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FAR1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label FAR1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...